ACORQ has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ACORQ has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Acorda Therapeutics's cash flow for dividends for the three months ended in Mar. 2024 was $0.00 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil.
Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.
The historical data trend for Acorda Therapeutics's Cash Flow for Dividends can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Acorda Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Cash Flow for Dividends | Get a 7-Day Free Trial | - | - | - | - | - |
Acorda Therapeutics Quarterly Data | ||||||||||||||||||||
Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | |
Cash Flow for Dividends | Get a 7-Day Free Trial | - | - | - | - | - |
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Cash Flow for Dividends for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Acorda Therapeutics's Cash Flow for Dividends provided by GuruFocus.com. Please click on the following links to see related term pages.
Thomas M. Burns | director | 2910 SEVENTH STREET, BERKELEY CA 94710 |
Ron Cohen | officer: CEO and President | C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502 |
John Varian | director | ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555 |
Michael A Gesser | officer: Chief Financial Officer | 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502 |
Neil S. Belloff | officer: General Counsel | 11 RADNOR LANE, MAHOPAC NY 10541 |
Kerry M Clem | officer: Chief Commercial Officer | 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502 |
Robert Morales | officer: Interim PAO & PFO | 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502 |
Jane Wasman | officer: Exec V Pres, Gen Cnsl & Sec | C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502 |
Lauren M Sabella | officer: Exec. VP-Commercial Dvlpmnt | C/O ACORDA THERAPEUTICS, 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502 |
David Lawrence | officer: Chief Financial Officer | C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502 |
Scopia Capital Management Lp | 10 percent owner | 152 WEST 57TH STREET, 33RD FLOOR, NEW YORK NY 10019 |
Lorin Randall | director | C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502 |
Burkhard Blank | officer: Chief Medical Officer | C/O ACORDA THERAPEUTICS, 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502 |
Scopia Management, Inc. | 10 percent owner | 152 WEST 57TH STREET, 33RD FLOOR, NEW YORK NY 10019 |
Matthew Sirovich | 10 percent owner | C/O SCOPIA MANAGEMENT INC, 450 SEVENTH AVENUE, 43RD FLOOR, NEW YORK NY 10123 |
From GuruFocus
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 02-06-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.